![conference banner](/images/conference-banner.jpeg)
Abstract
Site-directed antibodies which modulate conformation of β-amyloid peptide became the theoretical basis of the immunological approach for treatment of Alzheimers disease (AD). Indeed, antibodies towards the EFRH sequence, located between amino acids 3-6 of the N-terminal region of Alzheimers AβP, found to be a key position in protein conformation modulation, suppress formation of β-amyloid and dissolve already formed fibrillar amyloid. The performance of anti-β-amyloid antibodies in transgenic mice models of AD showed they are delivered to the central nervous system (CNS), preventing and dissolving β-amyloid plaques. Moreover, these antibodies protected the mice from learning and age-related memory deficits. Naturally occurring anti-AβP antibodies have been found in human CSF and in the plasma of healthy individuals, but were significantly lower in AD patients, suggesting that AD may be an immunodeficient disorder. Active and / or passive immunization against β-amyloid peptide has been proposed as a method for preventing and / or treating Alzheimers disease. Experimental active immunization with Aβ 1-42 in humans was stopped in phase II clinical trials due to unexpected neuroinflammatory manifestations. Antibodies generated with this first-generation vaccine might not have the desired therapeutic properties to target the ‘;correct’; mechanism, however, new clinical approaches are now under consideration. Immunotherapy represents fascinating ways to test the amyloid hypothesis and offers genuine opportunities for AD treatment, but requires careful antigen and antibody selection to maximize efficacy and minimize adverse events.
Keywords: alzheimer disease, monoclonal antibodies, abp, immunotherapy, n-terminal region, amyloid plaque, immunodeficiency, neuroinflammation
Current Alzheimer Research
Title: Alzheimers Disease and Immunotherapy
Volume: 1 Issue: 3
Author(s): Beka Solomon
Affiliation:
Keywords: alzheimer disease, monoclonal antibodies, abp, immunotherapy, n-terminal region, amyloid plaque, immunodeficiency, neuroinflammation
Abstract: Site-directed antibodies which modulate conformation of β-amyloid peptide became the theoretical basis of the immunological approach for treatment of Alzheimers disease (AD). Indeed, antibodies towards the EFRH sequence, located between amino acids 3-6 of the N-terminal region of Alzheimers AβP, found to be a key position in protein conformation modulation, suppress formation of β-amyloid and dissolve already formed fibrillar amyloid. The performance of anti-β-amyloid antibodies in transgenic mice models of AD showed they are delivered to the central nervous system (CNS), preventing and dissolving β-amyloid plaques. Moreover, these antibodies protected the mice from learning and age-related memory deficits. Naturally occurring anti-AβP antibodies have been found in human CSF and in the plasma of healthy individuals, but were significantly lower in AD patients, suggesting that AD may be an immunodeficient disorder. Active and / or passive immunization against β-amyloid peptide has been proposed as a method for preventing and / or treating Alzheimers disease. Experimental active immunization with Aβ 1-42 in humans was stopped in phase II clinical trials due to unexpected neuroinflammatory manifestations. Antibodies generated with this first-generation vaccine might not have the desired therapeutic properties to target the ‘;correct’; mechanism, however, new clinical approaches are now under consideration. Immunotherapy represents fascinating ways to test the amyloid hypothesis and offers genuine opportunities for AD treatment, but requires careful antigen and antibody selection to maximize efficacy and minimize adverse events.
Export Options
About this article
Cite this article as:
Solomon Beka, Alzheimers Disease and Immunotherapy, Current Alzheimer Research 2004; 1 (3) . https://dx.doi.org/10.2174/1567205043332126
DOI https://dx.doi.org/10.2174/1567205043332126 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Drug Targets and Delivery of Anti-HIV Drugs
Infectious Disorders - Drug Targets Common Neuropsychiatric Symptoms in Alzheimer’s Disease, Mild Cognitive Impairment, and Subjective Memory Complaints: A Unified Framework
Current Alzheimer Research Drug Targeting to the Brain - A Review
Current Nanoscience Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Kallikrein-Kinin System Mediated Inflammation in Alzheimers Disease In Vivo
Current Alzheimer Research Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Commentary: Death Associated Protein Kinase 1: A Perp in Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease
Current Neuropharmacology Synaptic Aging is Associated with Mitochondrial Dysfunction, Reduced Antioxidant Contents and Increased Vulnerability to Amyloid-β Toxicity
Current Alzheimer Research Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS
Current Alzheimer Research Diabetes Mellitus and Energy Dysmetabolism in Alzheimer’s Disease: Understanding the Relationships and Potential Therapeutic Targets
Current Diabetes Reviews Apolipoprotein E Knockout Models
Current Pharmaceutical Design Association Between sRAGE and Arterial Stiffness in Women with Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets A Short Review of Diffusion Models and their Possibilities to Enhance Imaging Biomarkers for Neurodegenerative Diseases
Current Medical Imaging HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry The Novel Derivatives of 3-(iminomethyl)-2H-chromen-2-one with Thiourea and Piperazine Structural Motive: Rationale, Synthesis, Antimicrobial and Anti-TB Evaluation
Letters in Drug Design & Discovery Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research